MRNA Moderna, Inc.

With potential profit-taking on the horizon, it could mean Moderna's upside is limited in the short-term.

Citigroup just told investors to sell Moderna and the stock responded by climbing 3%, raising one pointed question about whether pipeline optimism has fully broken free from Wall Street's valuation warnings.

Moderna stock rallied by triple digits when positive news rolled in for its cancer vaccine. But is mRNA ready to return to the limelight?

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6% in the morning session after Citigroup downgraded the company to Sell from Neutral, warning that a 222% rally had pushed its valuation to unsustainable levels.

Moderna stock has rallied since the company unveiled clinical updates to its cancer vaccine in collaboration with Merck in late August.

Moderna Stock Takes a Hit After Citi Raises Red Flag on Cancer Pipeline

After nearly quadrupling over the past month, it's time to get out of Moderna stock, a Citi analyst said Wednesday as he downgraded shares.

Citigroup just slapped a Sell rating on one of 2026's most explosive biotech stocks, warning that soaring investor hopes around a cancer vaccine partnership with Merck have carried the valuation into dangerous territory.

Target upgraded, Moderna downgraded: Wall Street's top analyst calls

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.01% and the actively t

Moderna falls after Citi downgrades shares to Sell from Hold, saying its recent rally has gone too far.

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock

Citi downgrades Moderna to Sell from Hold, saying the data around its cancer vaccine, instimeran autogene, isn’t enough to justify the valuation.

Citi downgraded Moderna to 'Sell' on valuation concerns after a massive 2026 rally, while investors await detailed Phase 3 melanoma data at ESMO next month.

Rising Treasury yields are rattling markets heading into the final trading day of Q3, and Wall Street analysts are making bold moves on a wide range of stocks from big-box retail to AI infrastructure. Find out who got cut and who got a fresh vote of confidence.

Investing.com - U.S. stock index futures hovered around the flatline on Wednesday, as investors turned their focus to key inflation data closely watched by the Federal Reserve and upcoming earnings from semiconductor group Micron.

September turned out to be a mediocre month for S&P 500 investors. But some stocks wound up having a great month.

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

Positive news surrounding its personalized cancer vaccine has lit a fire under the healthcare stock.

Laidlaw analyst Yale Jen flagged possible data in other cancers from 2027, while warning that personalized manufacturing costs, capacity and reimbursement could limit commercial success.

Investors rewarded companies with strong artificial intelligence demand, enterprise infrastructure, and drug development.

Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says.

In recent weeks, Moderna and Merck reported that their Phase 3 INTerpath-001 trial of personalized cancer vaccine intismeran autogene plus Keytruda met its primary endpoint in melanoma, with full data presented earlier this month at the European Society for Medical Oncology Congress 2026 and accompanied by growing oncology-focused pipeline visibility. At the same time, Moderna’s talks with Middle East partners about potential investment and manufacturing cooperation highlight how its mRNA...

Moderna (NasdaqGS:MRNA) entered high-level investment talks with the UAE government on advanced pharmaceutical manufacturing and R&D collaboration. The discussions focus on expanded research capabilities, potential local production, and broader access to Middle Eastern healthcare markets. Management framed the UAE engagement as part of a wider push to build out Moderna's international footprint beyond existing Western partnerships. The UAE collaboration talks matter, but investors also need...

Moderna (MRNA) concluded the recent trading session at $198.88, signifying a +2.08% move from its prior day's close.

Fresh analyst commentary put the spotlight on Moderna’s expanding mRNA cancer pipeline and Precigen’s transition into a commercial-stage biotech following the FDA approval of Papzimeos.

Dow, Nasdaq, and S&P 500 all gain ground despite climbing bond yields, with AI stocks leading the charge, today, Sept. 25, 2026.

Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says.

Moderna’s share price popped in August on positive news about its therapeutic cancer vaccine to prevent melanoma from recurring. At Journal House, United Nations General Assembly yesterday, the Journal’s Cynthia Koons asked CEO Stéphane Bancel: Why not enter oncology sooner? Bancel’s answer was a case study in making reasonable bets when the stakes are high.

Key TakeawaysOncology Repricing: Moderna stock jumped 7% on Thursday, September 24, closing at $195 as investors kept betting on intismeran autogene’s Phase 3 melanoma data due at ESMO on October 24. Street Split: The 23 analysts covering Moderna stock are split 4 buys, 1 outperform, 16 holds, 1 underperform, and 1 sell, with a mean target of $120 that sits 39% below Thursday’s close.

Five smaller stocks with market caps above $100 million beat MRNA’s monthly gain: INDP rose 249%, CYPH 124%, MNOV 85%, GRAL 58% and SRZN 53%.

Moderna Inc. (NASDAQ:MRNA) saw its share price climb to a new four-year high on Thursday, as investors cheered news that it was exploring investment opportunities in the Middle East. In intra-day trading, the stock climbed to a record high of $195.71 before trimming gains to finish the session just up by 6.98 percent at $194.82 […]

The stock was most recently helped by the company CEO’s optimism on its potential outside of COVID vaccines.

Chief executive Stéphane Bancel shares what’s next for Moderna after its report of a breakthrough of its cancer vaccine. He also discusses the state of the FDA and competition from China, AI integration in the drug industry and bioterrorism readiness.

Meta Platforms, Moderna and Okta rallied to fresh 52-week highs on Wednesday amid positive company catalysts and improving investor sentiment.

Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been’ just a Covid vaccine company.

Moderna and Twilio climbed to multi-year highs on Wednesday, fueled by optimism around Moderna’s broader mRNA pipeline and Twilio’s emerging opportunity from the rapid adoption of AI agents.

Moderna (NASDAQ:MRNA) executives emphasized the company’s evolution beyond COVID-19 vaccines during a discussion with Bernstein, highlighting its mRNA platform, personalized cancer vaccine program intismeran, rare-disease pipeline and plans to expand therapeutics development. Chief Executive Office

Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts.

There's a joke on Wall Street that analysts never saw an S&P 500 stock they didn't like. Well, that doesn't seem to be the case now.

Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts.

Moderna (NasdaqGS:MRNA) co-founder Bob Langer has joined the scientific advisory board of Cellular Intelligence, a biotech focused on AI-driven drug development. The appointment aligns with Cellular Intelligence's recent acquisition of a Parkinson's cell therapy program, linking AI discovery with advanced neurology research. Langer's role connects Moderna's mRNA expertise with a growing network of AI medicine collaborations involving Cellular Intelligence and its new Parkinson's therapy...

Moderna has delivered a very large 1 year share price gain, which puts fresh attention on a basic question. Is the current valuation of the stock supported by the company’s sales profile rather than just recent momentum and headlines? The stock is up a very large amount over the past 12 months, which makes the link between Moderna’s market value and its underlying sales more important for anyone thinking about valuation risk. News around mRNA products, from the mFlusiva flu vaccine launch to...

The company is looking to prove it can achieve significant success outside the coronavirus market.

Moderna (MRNA) stock rose roughly 510% over the year to September 21, 2026, climbing from about $25 to about $173. The S&P 500 gained 18.5% with dividends reinvested over the same window, and Pfizer (PFE) about 23%. The run's central event came on August 19, 2026, when Merck and Moderna said a Phase III trial of their cancer vaccine, intismeran autogene, met its endpoints in melanoma. A rough timetable for the trial was public long before the stock moved, but its result was not.

Following last month's super rally, a growing number of analysts are now calling for caution.

Moderna has surged over 500% this year while its closest messenger RNA rival sits nearly flat, and a single late-October data presentation at ESMO could either cement the rally or erase it overnight.

Moderna's 52-week high follows positive melanoma results, with detailed phase III data set for an ESMO presentation.

Key TakeawaysPresidential Symposium Slot: Moderna stock jumped 12% to $173 on September 21 after Phase 3 melanoma data for its cancer vaccine, intismeran autogene, earned a spot in ESMO’s Presidential Symposium on October 24. Vaccine Clearance: The FDA cleared updated Spikevax and mNEXSPIKE shots targeting the JN.

Advanced Micro Devices, Warner Bros. Discovery and Moderna stocks surged to annual highs amid a series of positive catalysts.